Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
For locally advanced gastric cance, neoadjuvant chemotherapy can increase the resectability
of tumor, and finally improve the long-term survival.
Combination of perioperative PD-1 antibody and chemotherapy for locally advanced gastric
cancer could be a novel therapy to increase response rate and resectability and reduce
recurrence rate. Camrelizumab（SHR-1210） in this study is a Chinese anti-PD-1 monoclonal
antibody for injection which has been approved for melanoma and Hepatocellular carcinoma.
This study is a single center, open-label, randomized comparative phase II clinical trial to
evaluate safety and efficacy of Camrelizumab in combination with perioperative chemotherapy
in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Differences in T
cell expression were detected by single cell RNA sequencing to screen people who were more
sensitive to immunotherapy.